BioStem Technologies, Inc. (BSEM)
| Market Cap | 80.04M |
| Revenue (ttm) | 47.48M |
| Net Income (ttm) | -6.58M |
| Shares Out | 16.96M |
| EPS (ttm) | -0.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,403 |
| Average Volume | 61,408 |
| Open | 4.560 |
| Previous Close | 4.600 |
| Day's Range | 4.550 - 4.740 |
| 52-Week Range | 3.093 - 15.500 |
| Beta | 0.18 |
| RSI | 48.03 |
| Earnings Date | May 12, 2026 |
About BioStem Technologies
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human conne... [Read more]
Financial Performance
Financial StatementsNews
BioStem Technologies Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is transforming into a regenerative medicine platform with a focus on surgical and hospital markets, driven by strategic acquisitions and a robust clinical and IP foundation. Expansion into new markets and internalizing manufacturing are expected to improve margins and support sustained growth.
BioStem Technologies Earnings Call Transcript: Q4 2025
Q4 2025 revenue was $10.1M with 97% gross margin, but physician office sales declined due to CMS changes. The hospital segment is now the main growth driver, supported by the BioTissue acquisition and expanded product portfolio. Cash runway extends into late Q3 2026.
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Le...
BioStem Technologies Transcript: TD Cowen 46th Annual Health Care Conference
The company is evolving into a diversified regenerative medicine platform, expanding its addressable market through acquisitions and new technologies. Strong clinical evidence, a broadened reimbursement base, and operational investments position it for growth and a potential Nasdaq up-listing.
BioStem Technologies Transcript: M&A announcement
The acquisition of BioTissue's surgical and wound care business doubles the addressable market, expands the product portfolio, and strengthens commercial reach, with $29 million in 2025 sales and 65% gross margins. Integration plans focus on seamless transition, tech transfer, and leveraging synergies for growth and profitability in 2026.
BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies
BioTissue Deepens Commitment to Ocular Market Leadership MIAMI, Jan. 21, 2026 /PRNewswire/ -- BioTissue Holdings, Inc, a leader in harnessing the unique properties of human birth tissue to facilitate ...
BioStem Technologies Earnings Call Transcript: Q3 2025
Delivered seventh straight quarter of positive adjusted EBITDA and industry-leading gross margins, despite lower revenue due to pricing pressures. Restated financials had no impact on EBITDA or net income. Positioned for growth with new clinical data, expanded market access, and upcoming CMS reimbursement reform.
BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant
POMPANO BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercializatio...
BioStem Technologies Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
A medtech firm specializing in placental-based wound care is rapidly expanding through clinical validation, strategic partnerships, and efficient manufacturing. Regulatory changes and new clinical data are expected to shape future growth, with strong financial performance and ongoing M&A opportunities supporting long-term expansion.
BioStem Technologies Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A proprietary wound care technology platform is driving rapid revenue growth, with strong clinical trial progress and a robust patent portfolio. Anticipated reimbursement changes in 2026 are expected to support further expansion, while new leadership and strategic partnerships position the company for continued success.
BioStem Technologies Earnings Call Transcript: Q2 2025
Q2 2025 saw a 34% revenue decline year-over-year due to reimbursement uncertainty and competition, but gross margins improved to 98.6% and cash rose to $30.8 million. Strategic shifts and clinical progress aim to restore growth amid ongoing regulatory and market headwinds.
BioStem Technologies Earnings Call Transcript: Q1 2025
Record Q1 revenue grew 73% year-over-year to $72.5 million, with strong profitability and cash flow. Commercial momentum for VENDAJE AC continues, despite LCD-related market headwinds and ongoing SEC review for NASDAQ uplisting.
BioStem Technologies Transcript: Centri Capital Conference 2025
A regenerative medicine company achieved record 2024 revenue over $301 million, driven by innovative wound care products and a strategic partnership with Venture Medical. Ongoing clinical trials and a pending Nasdaq uplisting support expansion into new markets and care settings.
BioStem Technologies Earnings Call Transcript: Q4 2024
Record revenue and net income were achieved in 2024, driven by strong product launches and market demand. Gross margins remained high, and cash position improved, while ongoing SEC and regulatory matters present some uncertainty. Uplisting to Nasdaq is anticipated soon.
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-...
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies CEO to Present at Biotech Showcase 2025
POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies Earnings Call Transcript: Q3 2024
Q3 2024 saw record revenue of $82.6M, 95% gross margin, and $9.9M adjusted EBITDA, driven by AmnioWrap2. Cash rose to $14.6M, and clinical trials plus a Nasdaq uplisting are underway, supporting continued growth and market expansion.
BioStem Technologies Transcript: 17th Annual LD Micro Main Event Conference
Four advanced wound care products, processed with proprietary BioRetain technology, are distributed exclusively through Venture Medical, driving rapid revenue growth and market expansion. Ongoing clinical trials and strong retrospective data support payer expansion and product differentiation.
BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT
Presentation to be webcast, with management participating in 1-on-1 meetings at the Luxe Sunset Boulevard Hotel in Los Angeles Pompano Beach, Florida--(Newsfile Corp. - October 23, 2024) - BioStem Tec...
BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
POMPANO BEACH, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-der...
BioStem Technologies Earnings Call Transcript: Q2 2024
Record Q2 revenue and profitability driven by AmnioWrap2, with gross margin at 95% and net income of $6.4M. Strategic initiatives include clinical trials, NASDAQ uplisting, and manufacturing expansion, positioning the company for continued growth despite potential regulatory changes.
BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments
Miami, Florida--(Newsfile Corp. - July 16, 2024) - Innovation is the lifeblood of the MedTech sector. Literally.
UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
Please note: this Update is being issued for ticker indexing purposes. The content of the release itself remains the same.
PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive interview with Jason Matuszewski, CEO of BioStem Technologies, Inc. ( OTC: BSEM). Following a successful start to 20...